Geron Corporation is a commercial-stage biopharmaceutical company focused on developing oncology therapeutics. Its pipeline includes RYTELO, a telomerase inhibitor approved for adults with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. Other candidates include IMerge (Phase 3 for lower-risk myelodysplastic syndromes), IMpactMF (Phase 3 for relapsed/refractory myelofibrosis), Impress (Phase 2 for higher-risk myelodysplastic syndromes and acute myeloid leukemia), IMproveMF (Phase 1 for frontline myelofibrosis), and IMAGINE (Phase 1/2 for relapsed/refractory acute myeloid leukemia). Incorporated in 1990, the company is headquartered in Foster City, California.
Bristol Myers' Reblozyl Sales Near $1.3 Billion as FDA Sets 2027 Decision Date
Bristol Myers Squibb is counting on Reblozyl, the thalassemia drug it co-developed with Merck, to help drive top-line growth as legacy drug sales decline, with the treatment's sales nearing $1.3 billion in the first half of 2026, up 23% from the year-ago period. The drug's strong sales reflect solid uptake in first-line MDS-associated anemia, continued strength in the second-line setting and further penetration in the first-line RS-negative population. The FDA has accepted a supplemental biologics license application for Reblozyl with concomitant janus kinase inhibitor therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell transfusions, supported by the late-stage INDEPENDENCE study, and granted a target action date of March 11, 2027. A phase III study called ELEMENT-MDS, evaluating Reblozyl in first-line non-transfusion dependent low or intermediate risk MDS associated anemia, is ongoing, with data expected in 2028. In the competitive landscape, Geron Corporation's Rytelo generated $57.5 million of revenues in the second quarter of 2026 and is expected to post 2026 sales of $220-$240 million, while Keros Therapeutics expects a $20 million development milestone payment from partner Takeda after dosing the first patient in the late-stage ELRiSE MF study.
Biotech & Genomic Medicine › Oncology Therapeutics Demand
BMY · Demand · Positive Reblozyl sales near $1.3B in H1 2026, up 23% on strong uptake in first-line MDS-associated anemia and other settings.
BMY · Regulation · Positive FDA accepted supplemental BLA for Reblozyl with JAK inhibitor therapy in myelofibrosis-associated anemia, setting a March 11, 2027 action date.
MRK · Demand · Positive Merck co-developed Reblozyl, whose sales near $1.3B in H1 2026, up 23%, benefiting its partnered drug.
GERN · Competition · Neutral Geron's Rytelo posted $57.5M in Q2 2026 revenue and is expected to reach $220-$240M in 2026, mentioned as a competitor in the landscape.
KROS · Capital · Neutral Keros expects a $20M development milestone payment from Takeda after dosing the first patient in the ELRiSE MF study.
Geron Eyes High End of 2026 RYTELO Revenue Guidance
Geron Corporation said it now expects 2026 RYTELO net revenue toward the midpoint to high end of its previously issued $220 million to $240 million guidance, or approximately $230 million to $240 million. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executive Officer Harout Semerjian said the company reported record quarterly net revenue of $57.5 million, its highest since the July 2024 launch of RYTELO, also known as imetelstat, the first telomerase inhibitor approved for lower-risk myelodysplastic syndromes, with three consecutive quarters of growth. Geron is shifting commercial efforts toward community oncology practices, which account for about 80% of the lower-risk MDS market, and is adding 100 to 200 new RYTELO accounts per quarter, while 34% of its business, measured on a 12-month lookback, already comes from first- and second-line patients. Chief Medical Officer Joseph Eid said National Comprehensive Cancer Network guidelines have been updated twice since launch to position the therapy as a second-line option, and that luspatercept's move to first-line treatment has supported RYTELO uptake. Geron plans to outline its ex-U.S. strategy, particularly for Europe, before year-end without a traditional large-scale country-by-country buildout, and continues the 327-patient IMpactMF Phase 3 trial in relapsed or refractory myelofibrosis, which completed enrollment last September with overall survival as the primary endpoint. The company ended the period with more than $300 million in cash and reiterated 2026 operating-expense guidance of $230 million to $240 million.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
GERN · Capital · Positive Geron guided 2026 RYTELO revenue toward the midpoint-to-high end of $220-240M and reported record quarterly net revenue of $57.5M with three consecutive quarters of growth.
GERN · Demand · Positive Geron is adding 100-200 new RYTELO accounts per quarter, shifting to community oncology, and NCCN guidelines position the therapy as a second-line option supporting uptake.
Geron Issues First RYTELO Revenue Guide, Narrows Losses
Geron Corporation reported second-quarter 2026 revenue of US$57.48 million, up from US$49.04 million a year earlier, and a net loss of US$16.68 million, while issuing its first full-year 2026 RYTELO net product revenue guidance of US$220 million to US$240 million. First-half revenue reached US$109.32 million and the first-half net loss narrowed to US$20.32 million. The company also filed a US$6.03 million common stock shelf registration for 4,500,000 shares tied to an employee stock ownership plan. The reiterated guidance sharpens focus on the launch trajectory of Geron's sole commercial therapy, RYTELO, as the company remains dependent on a single drug and faces ongoing cash needs.
Several biotech companies posted sharp gains on Wednesday, led by Attovia Therapeutics' 28% surge on its Nasdaq debut and American Well's 25% jump after narrowing its quarterly loss. Attovia priced its IPO at $17 per share and closed at $21.90, while American Well reported a net loss of $9.6 million, or $0.59 per share, down from $19.5 million, or $1.24 per share, a year earlier, though revenue fell to $52.0 million from $70.9 million. Perrigo swung to a net income of $74.5 million, or $0.53 per share, from a loss of $8.4 million, or $0.06 per share, despite a slight revenue dip to $1.02 billion. UroGen Pharma climbed over 16% after total revenue more than doubled to $72.5 million, driven by its bladder cancer drug ZUSDURI, and its net loss narrowed to $14.4 million from $49.9 million. Geron rose 21% as net product revenue increased to $57.5 million from $49.0 million, fueled by higher RYTELO sales, and it forecast full-year RYTELO revenue of $220 million to $240 million.
Geron Grants Inducement Stock Options to Eight New Employees
Geron Corporation granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees, effective June 17, 2026. The grants were made as an inducement material to the employees' acceptance of employment. The options have an exercise price of $1.23 per share, equal to the closing price on the grant date, and a ten-year term. They vest over four years, with 12.5% of the shares vesting on the six-month anniversary of employment commencement and the remaining shares vesting over the following 42 months in equal installments, subject to continued employment.
Geron Appoints Chinmaya Rath as Chief Business Officer
Geron Corporation has appointed Chinmaya Rath as its new Chief Business Officer. Rath brings over 25 years of biopharma leadership experience, including a significant tenure at Novartis where he led enterprise-wide strategic initiatives such as the integrations of GSK Oncology and Alcon. Most recently, he served as Head of Pharma Solutions at Cellworks and Chief Business Officer at GlycoMimetics. Geron's President and CEO Harout Semerjian stated that Rath's appointment underscores the company's dedication to maximizing the value of RYTELO globally and building a leading hematology company. Rath highlighted RYTELO's best-in-class profile and strong commercial performance in lower-risk myelodysplastic syndromes as positioning Geron for continued growth.
United States
Japan